Johnson & Johnson / Aragon Pharmaceuticals Inc.

Castration-Resistant Prostate Cancer (CRPC)

239K US cases/yr

Disease Overview

Castration-resistant prostate cancer is advanced prostate cancer that progresses despite androgen-deprivation therapy. Despite suppressed testosterone, tumors continue signaling through the androgen receptor via mutations, amplifications, splice variants, and intratumoral androgen synthesis — creating a target for next-generation AR-pathway inhibitors. mCRPC remains lethal, though survival improved meaningfully with Zytiga, Xtandi, sipuleucel-T, cabazitaxel, and Xofigo.

Competitive Landscape

By mid-2013, the CRPC market had pivoted into a multi-asset oral-AR-pathway era. Janssen's Zytiga (abiraterone, CYP17 inhibitor + prednisone) was approved 2011 in post-chemo and April 2012 in chemo-naive mCRPC. Medivation/Astellas' Xtandi (enzalutamide), an AR antagonist, gained FDA approval August 2012 in post-chemo mCRPC after the AFFIRM trial showed a 4.8-month OS benefit, with chemo-naive expansion and earlier-line moves to follow. Sanofi's Jevtana (cabazitaxel) and Dendreon's Provenge (sipuleucel-T) provided chemotherapy and immunotherapy options; Bayer's Xofigo (radium-223) added a bone-metastatic option in May 2013. Aragon's ARN-509 was a second-generation AR signaling inhibitor positioned as a potential best-in-class follow-on to enzalutamide — with deeper AR antagonism, lower CNS penetration, and the strategic potential for combination with J&J's own Zytiga. J&J's $650M upfront / up to $350M milestone deal closed August 19, 2013; Aragon spun out its non-AR estrogen-receptor degrader program into Seragon (later sold to Genentech for up to $1.7B in 2014). ARN-509 ultimately became Erleada (apalutamide), FDA-approved February 2018 for nmCRPC, with later mCSPC expansion. Source: https://www.fiercebiotech.com/financials/j-j-snags-another-promising-prostate-cancer-drug-1b-aragon-buyout